Lung Cancer


The purpose of this study is to assess the efficacy and safety of durvalumab versus placebo following SoC chemotherapy in patients with completely resected stage II-III NSCLC who are MRD+ post surgery

Trial overview


Carcinoma, non-small cell lung


A Phase III, Randomised, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination With Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC.

Eligibility criteria

  • Early Stage Non-Small Cell Lung Cancer requiring surgery
  • No known mutations in the lung cancer

Study details

This study requires tumour tissue and blood tests close to the date of the lung cancer surgery. This assessment determines the eligibility for the trial.

The treatment is the standard of care chemotherapy for lung cancer with the addition of durvalumab.

While on treatment there will be regular blood tests and scans to monitor progress. At completion of treatment the study will continue to follow your progress.

Further information

For more information regarding this clinical trial click here.


Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.